Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹395Cr
Rev Gr TTM
Revenue Growth TTM
3.29%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

KAYA
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 10.9 | -35.7 | -44.5 | -45.6 | -44.0 | -13.1 | 3.6 | 6.8 | 5.5 | 1.8 | 2.5 | 3.3 |
| 117 | 53 | 41 | 44 | 117 | 46 | 47 | 53 | 53 | 49 | 57 | 71 |
Operating Profit Operating ProfitCr |
| -26.7 | 10.5 | 18.8 | 19.5 | -126.1 | 11.1 | 10.8 | 8.2 | 3.1 | 7.0 | -6.2 | -19.1 |
Other Income Other IncomeCr | 1 | 1 | 1 | 1 | 2 | 11 | 1 | 1 | 4 | 1 | 4 | -4 |
Interest Expense Interest ExpenseCr | 17 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 |
Depreciation DepreciationCr | 16 | 10 | 9 | 9 | 9 | 9 | 9 | 10 | 9 | 10 | 11 | 12 |
| -56 | -9 | -4 | -4 | -79 | 0 | -11 | -11 | -11 | -14 | -19 | -36 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | -36.3 | 59.5 | 29.5 | 49.6 | -76.0 | 1,089.4 | -34.6 | 141.1 | 92.9 | -113.7 | -19.7 | -1,066.3 |
| -60.9 | -17.4 | -23.0 | -16.5 | -191.5 | 198.1 | -29.8 | 6.3 | -12.8 | -26.7 | -34.8 | -59.2 |
| -43.1 | -7.9 | -8.9 | -6.9 | -75.9 | 78.6 | -12.0 | 2.8 | -5.4 | -10.8 | -13.2 | -23.4 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 11.3 | 10.9 | -2.4 | 5.1 | -6.6 | -30.1 | 17.8 | 16.3 | -45.5 | 5.8 | 1.9 |
| 300 | 357 | 400 | 403 | 412 | 343 | 252 | 310 | 401 | 242 | 199 | 231 |
Operating Profit Operating ProfitCr |
| 9.8 | 3.6 | 2.5 | -0.8 | 2.0 | 12.8 | 8.3 | 4.3 | -6.5 | -18.1 | 8.2 | -4.2 |
Other Income Other IncomeCr | 11 | 12 | 10 | 9 | 2 | 9 | 15 | 12 | 5 | 5 | 17 | 6 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 3 | 17 | 15 | 16 | 36 | 26 | 31 | 34 |
Depreciation DepreciationCr | 12 | 17 | 20 | 24 | 29 | 75 | 60 | 78 | 61 | 35 | 38 | 42 |
| 32 | 9 | 0 | -20 | -21 | -33 | -37 | -68 | -116 | -94 | -33 | -80 |
| 0 | 0 | 0 | 0 | -6 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| | -72.1 | -102.0 | -11,203.1 | 21.2 | -247.4 | 30.9 | -81.7 | -71.1 | 19.4 | 64.4 | -126.1 |
| 9.6 | 2.4 | 0.0 | -4.9 | -3.7 | -13.8 | -13.6 | -21.0 | -30.9 | -45.7 | -15.4 | -34.1 |
| 24.6 | 6.8 | -21.7 | -15.2 | -12.2 | -41.7 | -29.1 | -52.7 | -89.2 | -98.9 | 64.0 | -52.7 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 0 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 |
| 222 | 238 | 238 | 197 | 145 | 69 | 41 | -15 | -117 | -240 | -153 | -108 |
Current Liabilities Current LiabilitiesCr | 129 | 142 | 143 | 137 | 180 | 189 | 182 | 196 | 249 | 286 | 142 | 145 |
Non Current Liabilities Non Current LiabilitiesCr | 9 | 13 | 31 | 23 | 29 | 138 | 131 | 166 | 224 | 236 | 234 | 255 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 232 | 231 | 185 | 120 | 115 | 95 | 78 | 106 | 143 | 102 | 66 | 111 |
Non Current Assets Non Current AssetsCr | 141 | 176 | 240 | 252 | 254 | 314 | 290 | 255 | 227 | 194 | 171 | 197 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 32 | 5 | -6 | -12 | 22 | 47 | 32 | 30 | 63 | 39 | 1 |
Investing Cash Flow Investing Cash FlowCr | -17 | -6 | -41 | 24 | -28 | -12 | 4 | -35 | -40 | -9 | 25 |
Financing Cash Flow Financing Cash FlowCr | 0 | 0 | 33 | -7 | 5 | -47 | -31 | 12 | -18 | -38 | -37 |
|
Free Cash Flow Free Cash FlowCr | -4 | -37 | -31 | -45 | -12 | 38 | 29 | 15 | 39 | 5 | -21 |
| 101.5 | 54.2 | 3,412.8 | 58.3 | -139.6 | -87.3 | -84.5 | -44.0 | -54.0 | -41.4 | -3.6 |
CFO To EBITDA CFO To EBITDA% | 98.5 | 35.9 | -59.1 | 375.4 | 257.0 | 93.9 | 139.0 | 217.2 | -258.1 | -104.3 | 6.8 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 1,110 | 1,014 | 1,361 | 935 | 146 | 387 | 458 | 331 | 410 | 306 |
Price To Earnings Price To Earnings | 0.0 | 126.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 |
Price To Sales Price To Sales | 0.0 | 3.0 | 2.5 | 3.4 | 2.2 | 0.4 | 1.4 | 1.4 | 0.9 | 2.0 | 1.4 |
Price To Book Price To Book | 0.0 | 4.4 | 4.4 | 6.5 | 5.9 | 1.8 | 7.1 | -294.4 | -3.2 | -1.8 | -2.2 |
| -0.9 | 80.9 | 100.8 | -441.1 | 110.5 | 5.9 | 23.2 | 46.2 | -21.6 | -18.6 | 31.0 |
Profitability Ratios Profitability Ratios |
| 91.2 | 89.4 | 89.5 | 96.6 | 96.2 | 95.6 | 96.1 | 96.7 | 96.5 | 93.2 | 93.0 |
| 9.8 | 3.6 | 2.5 | -0.8 | 2.0 | 12.8 | 8.3 | 4.3 | -6.5 | -18.1 | 8.2 |
| 9.6 | 2.4 | 0.0 | -4.9 | -3.7 | -13.8 | -13.6 | -21.0 | -30.9 | -45.7 | -15.4 |
| 14.3 | 3.5 | 0.1 | -8.3 | -10.3 | -6.8 | -10.9 | -25.9 | -55.5 | -90.8 | -2.3 |
| 14.3 | 3.5 | -0.1 | -9.4 | -9.9 | -66.3 | -68.7 | 4,372.9 | 112.1 | 41.3 | 23.9 |
| 8.5 | 2.2 | 0.0 | -5.3 | -4.2 | -13.2 | -10.2 | -18.8 | -31.4 | -31.7 | -14.1 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
#### **Overview**
Kaya Limited is India’s leading dermatology-led aesthetic healthcare provider, with a strong two-decade legacy since its founding in 2003 by Harsh Mariwala. Operating under a unique model that blends **medical expertise, retail innovation, and hospitality-driven customer experience**, Kaya has established itself as a category-defining brand in the organized aesthetic dermatology sector.
The company serves **over 3 million clients** across India through a nationwide network of **82 clinics**, staffed by **over 100 dermatologists** and supported by a team of trained beauty professionals. Kaya offers **600+ clinical service lines** and markets **75+ dermatologist-developed skincare, haircare, body care, and nutraceutical products** under the “Dermat Curated” philosophy.
Following a strategic refocus in 2024, Kaya has exited its Middle East operations (GCC entities), divesting Kaya DMCC and FZE to **Humania GCC Holding Limited**, to concentrate exclusively on accelerating growth in the high-potential Indian market.
---
#### **Core Business Segments**
Kaya’s business model is built around three integrated pillars:
1. **Clinical Services (86% of revenue in FY25):**
Delivering science-backed, dermatologist-guided treatments for skin, hair, and body concerns.
2. **Retail Products (14% of revenue in FY25):**
Featuring in-house R&D-developed formulations sold via clinics, e-commerce, and FMCG partnerships.
3. **Digital & Technology Platforms:**
Driving personalization, access, and engagement through AI, automation, and omnichannel integration.
---
#### **Key Service Offerings**
Kaya’s clinical portfolio targets high-demand aesthetic segments with medical precision:
- **Laser Hair Reduction (LHR):** A **key customer acquisition driver**, especially among men and women seeking long-term, non-invasive solutions. Uses FDA-approved **Alma Soprano Titanium** technology.
- **Anti-Ageing:** Comprehensive treatments including **Botox, fillers, HIFU, Profhilo, Dermafrac, Thermage FLX**, and chemical peels.
- **Pigmentation & Brightening:** Advanced, low-downtime therapies using **Q-Switch lasers, tailored chemical peels**, and post-care regimens.
- **Hair Regeneration:** Root-cause focused solutions like **PRP, GFC-PRP, Derma Roller, Nutri Infusions, and Regenera**, supported by scalp diagnostics.
- **Body Contouring & Sculpting:** In-demand services using **CoolSculpting, CM Slim, Venus Legacy, cryolipolysis, radiofrequency lipolysis**, and muscle stimulation technologies. Projected to grow at **14.9% CAGR (FY25–FY29)**.
- **Wellness & Inner Beauty:** **IV drip infusions (glutathione, vitamins), nutraceuticals (collagen peptides, hair & skin supplements)**.
---
#### **Product Portfolio and Innovation**
- **75+ dermatologist-developed SKUs** across skin, hair, and body care, including shampoos, serums, masques, oils, and lotions.
- **Nutraceuticals launched in FY25**, contributing **~5% of clinic collections**. Glutathione-based products account for **46% of the nutraceutical line**.
- Strategic **collaboration with Marico Limited** to expand retail footprint: Marico handles **marketing and distribution** of Kaya products across omni-channel platforms (Nykaa, Amazon, Flipkart, Blinkit, etc.), creating a **royalty-based income stream**.
- Product revenue from clinics stood at **₹2,887 lakh in FY25**, up from ₹2,746 lakh in FY24.
---
#### **Geographic Presence & Expansion Strategy**
- **82 clinics across India (as of Nov 2025)**, with recent launches in **Chennai, Pune, Ludhiana**, expanding to five clinics each in major metros.
- New clinic openings in **high-potential Tier 2 and Tier 3 cities** to capture underserved markets.
- All new and upgraded clinics feature **modern luxury designs**, **"body boutiques"**, and **immersive treatment suites** to reinforce **premium positioning**.
- **Exited Middle East market** (UAE, Oman, KSA) due to **persistent losses and geopolitical volatility**, allowing capital reallocation to India.
---
#### **Technology and Digital Transformation**
Kaya is a pioneer in leveraging technology to enhance clinical outcomes and customer experience:
- **Klear AI:** Proprietary AI-powered app trained on **thousands of Indian skin images** for faster, accurate diagnostics (ageing, acne, scars, pigmentation). Used for self-assessment and dermatologist support.
- **Kaya Doctor AI App:** Enables **predictive outcome modeling, personalized treatment planning**, and enhances consultation efficiency.
- **Omnichannel Platform:**
- D2C site **shop.kaya.in** with AI-driven recommendations.
- Clinic-facilitated fulfillment for same-day delivery.
- Integration with e-commerce (Amazon, Nykaa, Blinkit, Myntra).
- **Marketing Automation:**
- **24/7 WhatsApp and web chatbots** for appointment booking, reminders, and queries.
- Automated nudges and CRM systems boosted **conversion, retention, and customer satisfaction**.
- **Internal Systems:** Powered by **Microsoft Dynamics 365 and Power BI** for data-driven decision-making and operational efficiency.
---
#### **Marketing & Customer Engagement**
- **Kaya Smiles Loyalty Program:** Drives **over 90% of Indian clinic collections**, with **tiered benefits** and **experiential rewards**. Evolving from transactional to **relationship-led engagement**.
- **Digital-First Strategy:**
- Leverages **influencer marketing, educational content, skinfluencer dermatologists**, and **Gen Z-focused campaigns**.
- Focus on **outcome-based storytelling** and social media engagement (Instagram, Facebook, YouTube).
- **7% of revenue** allocated to marketing, emphasizing **digital, hyperlocal activations, and brand storytelling**.
- **AI and automation** contributed to incremental revenue, especially in **Acne and Brightening segments** (up to **26% increase**).
---
#### **Market Position & Competitive Landscape**
**Strengths:**
- Market leader in **LHR, anti-ageing, and pigmentation**.
- Nation’s **largest chain** of dermatologist-led aesthetic clinics.
- Strong **brand trust, scientific rigor, and medical integrity**.
- Early mover in **AI-enabled dermatology** and **digital diagnostics**.
**Challenges:**
- **High fixed costs** from physical clinic infrastructure.
- **Intense competition** from digital-first D2C brands and freelance dermatologists.
- **Scalability limitations** in a teledermatology-growing market.
- **Talent scarcity** in qualified dermatologists.
**Competitive Threats:**
- **At-home laser devices**, virtual consultations, and subscription-based models.
- Private equity-backed skincare startups with aggressive digital go-to-market.
---
#### **Strategic Priorities (FY26 and Beyond)**
1. **Accelerate India-Focused Growth:** Expand clinic network into **Tier 2/3 cities**.
2. **Enhance Body & Hair Verticals:** Position Kaya as a **360° skin, hair, and body leader**.
3. **Deepen Digital Integration:** Scale **AI tools**, upgrade D2C capabilities, and strengthen **data-led operations**.
4. **Optimize Clinics:** Renovate, relocate underperforming units, and deploy **next-generation tech**.
5. **Return to Profitability:** Achieve **operating leverage** through **scale, technology, and efficient operations**.
---
#### **Financial Highlights**
- **FY24 Collections:** INR **250.2 crore** (up 7% YoY from ₹234.6 crore).
- **Product Contribution:** 14% of total clinic collections.
- **LHR Services:** Account for **~29.9% of Indian clinic revenue**.
- **Body Contouring Segment:** Growing at **77% YoY (Q4 FY23)**.